Guardant Health

Today marks the start of Breast Cancer Awareness Month! Let’s unite to raise awareness, advocate for early detection, and strengthen our commitment in the fight against #BreastCancer. #NationalBreastCancerAwarenessMonth

Our co-CEOs?AmirAli Talasaz?and?Helmy Eltoukhy?are honored to participate as speakers tomorrow at the 2nd?Health Equity Forum?hosted at the?United Nations?during #UNGA79. This important discussion presents a valuable opportunity to engage with fellow industry leaders to explore innovative collaborations that advance health equity, ensuring a healthier future for all.

Last week, we announced the publication of data from the SCRUM-Japan GOZILA study in Nature Medicine. The results from the study show patients who received targeted treatment, guided by our Guardant360 CDx blood test, live approximately twice as long, highlighting the potential of liquid biopsy-guided treatment to improve patient outcomes. ? Full publication: https://bit.ly/3BdmIQx

We’re headed to #AAFPFMX this week in Phoenix! Join us at booth #2321 and at our Med Talk session this Thursday at 2:55pm to learn how?our recently FDA-approved and Medicare-covered Shield blood test can help overcome CRC screening adherence challenges.

We look forward to sharing data at the 2024 ESMO - European Society for Medical Oncology Congress, highlighting the critical role liquid biopsy plays in informing therapy selection and the strong performance of our precision oncology technology in multiple advanced tumor types. Press release and presentation details: https://bit.ly/4daVwPv #ESMO24

Via The Washington Post: Advancements in screening technologies, such as our Shield blood test, have the potential to revolutionize cancer care. However, the path to equitable access remains uncertain. It’s essential that policymakers address these barriers to fulfill the promise of better preventive care for all.

We’re pleased to announce our partnership with Fondazione Policlinico Universitario Agostino Gemelli IRCCS, establishing one of the first hospital-based liquid biopsy testing facilities in Italy. Our co-CEO Helmy Eltoukhy: “We’re thrilled to partner with Policlinico Gemelli, empowering clinicians to swiftly detect tumor alterations with a blood test, guiding personalized treatments, and fueling research innovation. This collaboration brings us closer to our mission of ensuring all cancer patients worldwide have access to the latest advancements for optimal care.”

Join us next Wednesday at the 14th Annual World Clinical Biomarkers & Companion Diagnostics Summit for an engaging plenary session led by Sara Wienke MS, CGC on enhancing the predictive power of liquid biopsy with a methylation-based approach to treatment response monitoring. More details:?https://world-cdx.com/

Discover the work behind our mission to conquer cancer with data as part of the Global Health documentary series, which spotlights innovative solutions to global health issues. Explore the full documentary and interview featured on Reuters: https://bit.ly/3AKUdJR

By ringing this morning's bell, we celebrate another pivotal moment in our journey to conquer cancer with data with the FDA approval and commercial launch of our Shield blood test! Thank you to our dedicated team, partners, and supporters who have made this achievement possible. Watch the opening ceremony: https://lnkd.in/gRGepS_c